Fluprostenol

Fluprostenol

SCHEMBL13260302

O=C(O)CCC/C=C\CC1C(O)CC(O)C1/C=C/C(O)COc1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 16/20 1.00
PTGER3 P43115 5/20 1.00
ABCC4 O15439 2/20 0.81
ABCB11 O95342 1/20 0.81
TBXA2R P21731 3/20 0.78
PTGER1 P34995 2/20 0.78
THRB P10828 1/20 0.78
PTGER2 P43116 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluprostenol SCHEMBL16414486 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL16414497 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL2744986 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL10015915 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL24342036 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL24342073 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL6750653 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL230607 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL20860290 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R
Fluprostenol SCHEMBL3364535 1.00 PTGFR (1.00) PTGFRPTGER3ABCC4ABCB11TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722739-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-05-13 US disclosed
US-8722739-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-05-13 US disclosed
US-20140031423-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. (US) 2014-01-30 US disclosed
US-20140031423-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. (US) 2014-01-30 US disclosed
US-8623918-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-01-07 US disclosed
US-8623918-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-01-07 US disclosed
US-8470882-B2 2013-06-25 US disclosed
US-8470882-B2 2013-06-25 US disclosed
WO-2010096123-A2 AMINO ACID SALTS OF PROSTAGLANDINS AERIE PHARMACEUTICALS, INC. (US) 2010-08-26 WO disclosed
US-20100105771-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed
US-20100105771-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed
US-20100105775-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed
US-20100105775-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105771-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR PTGFR 7/4885PTGER3 16/4885ABCC4 4544/4885
US-20100105775-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR PTGFR 7/4885PTGER3 16/4885ABCC4 4544/4885
US-20140031423-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR PTGFR 7/4885PTGER3 16/4885ABCC4 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.